PT  - JOURNAL ARTICLE
AU  - Matthew Benger
AU  - Jasper Vink
AU  - Luke Blagdon Snell
AU  - Karen Breen
TI  - Comparing APLS and oranges: caution with the use of direct-acting oral anticoagulants (DOACs) instead of warfarin in the treatment of antiphospholipid syndrome (APLS)
AID  - 10.1136/bcr-2018-227695
DP  - 2019 Apr 01
TA  - BMJ Case Reports
PG  - e227695
VI  - 12
IP  - 4
4099  - http://casereports.bmj.com/content/12/4/e227695.short
4100  - http://casereports.bmj.com/content/12/4/e227695.full
SO  - BMJ Case Reports2019 Apr 01; 12
AB  - A 63-year-old woman with known antiphospholipid syndrome (APLS) presented with catastrophic APLS and multiorgan dysfunction after a change in her anticoagulation from warfarin to rivaroxaban. Evidence suggests direct-acting oral anticoagulants (DOACs) like rivaroxaban may be less effective than warfarin in secondary prevention of thrombotic events in high-risk APLS patients.